Pfizer Inc.

PFE

FSX · XFRA · Germany

Financial Research and Analysis

Pfizer on the Frankfurt exchange

This page covers Pfizer's Frankfurt-associated listing, XFRA. The delayed reference quote was EUR 26.60 on 27 October 2026, down 0.21%. Previous close was EUR 26.65, with a session range of EUR 26.50 to EUR 26.79. Displayed volume was 2,101, and the reported 52-week range was EUR 20.70 to EUR 27.08. This is not a live market quotation.

Frankfurt valuation and distributions

The supplied dataset reports a trailing P/E of 39.27, forward P/E of 10.42 and indicated dividend yield of 5.60%. Historical and forward multiples measure different earnings periods. The dividend basis should be confirmed before comparing yields across venues. Currency, market hours and liquidity can produce differences in quotations.

Frankfurt listing questions

What is the quotation currency? Euro. What is the dated reference price? EUR 26.60 on 27 October 2026. Is it live? No, it is a delayed quote. Is its numerical price identical to the US quotation? Such equivalence cannot be assumed because currency, trading hours and venue differ.

Pfizer and its core businesses

Founded in 1849, Pfizer develops, manufactures and markets medicines and vaccines worldwide. Its portfolio includes Eliquis, Prevnar, Paxlovid and specialized oncology treatments. Research productivity, regulatory approvals, competition and product exclusivity are important drivers of business performance. Patent expiration, clinical trial costs and changes in medicine pricing are material risks.

Consolidated financial performance

The supplied figures show Pfizer revenue of USD 62.58 billion in 2025 versus USD 63.63 billion in 2024, a decline of 1.65%. Reported annual earnings were USD 7.77 billion. These represent the consolidated US issuer rather than separate results for Frankfurt trading or the Argentine depositary instrument. The financial condition of the company and the trading price of a local instrument are different concepts.

Product portfolio and growth prospects

Vaccines, oncology and specialty medicines remain important to Pfizer's business. The October 2026 materials provided refer to clinical developments involving ELREXFIO and expanded regulatory approvals for certain oncology treatments. Clinical progress alone does not establish commercial success. Regulatory authorization, competition, patient access, pricing and execution remain important variables.

Dividend sustainability

Evaluating Pfizer's dividends requires consideration of formal declarations, cash generation, financial obligations and investment in drug development. A historical or indicated dividend yield is not a guarantee of future payments. Investors in international instruments also need to assess withholding, custody fees, currency conversion and the instrument's specific economic rights.

Investment valuation and risks

Pfizer faces pharmaceutical competition, patent expiration, health-policy changes, litigation, clinical-development uncertainty and exchange-rate exposure. Price-to-earnings ratios must be assessed alongside the reporting period, earnings quality and security structure. A historical price rise or decline does not by itself establish investment value. This material is educational and is not investment advice.

Comparing earnings across reporting periods

Financial analysis starts with the reporting period associated with each figure. Annual revenue should not be compared directly with one quarter without adjusting for the period covered. Earnings per share may include nonrecurring effects, and accounting profits do not always match cash generated by operations. Liquidity, debt repayment and investment capacity depend on cash resources as well as reported earnings. Multi-year comparisons help distinguish changes in product demand from temporary accounting or restructuring effects.

Product exclusivity and the development pipeline

Intellectual-property rights are central to pharmaceutical economics. When product exclusivity expires, competing therapies may reduce revenue and pricing power. Investors therefore need to monitor expected exclusivity losses as well as new medicine approvals and launch execution. Experimental therapies should not be treated as certain future revenue streams. Clinical success, regulatory authorization, pricing access and commercial adoption are separate hurdles, each of which can materially influence an investment thesis.

Interest rates, financing and debt

Interest rates influence borrowing costs and the present value attributed to future cash flows. Higher financing expenses can constrain investment in research or acquisition opportunities, although operational performance is often more important than rate movements alone. Debt maturities, available liquidity and future commitments should be examined alongside cash generation. Lower interest rates do not automatically translate into better earnings if product sales, competitive dynamics or execution deteriorate.

Interpreting valuation multiples

A trailing earnings multiple relates price to realized earnings, while a forward multiple depends on projections that can change. A high P/E may result from temporarily depressed profits rather than an unusually high price. International depositary instruments introduce another complication because their quotation units, underlying-share ratios, currencies and provider methodologies can differ. A multiple should not be compared across instruments without confirming exactly which earnings and security units its calculation uses.

Dividend payments and foreign currency

Distribution analysis requires identifying the payment currency, entitlement per underlying share and the number of shares represented by each local instrument. Exchange conversion, custody charges, withholding arrangements and broker fees can all affect net investor receipts. A yield reported for a US share is not necessarily identical to the cash outcome for an international depositary certificate. Falling market prices can also raise an indicated yield without increasing the actual dividend payment.

Source methodology and data limitations

Quoted prices and market statistics in these profiles are dated reference observations rather than real-time market feeds. Different providers may report different percentage changes or capitalization measures because they capture separate moments or apply different instrument definitions. Conflicting values should be disclosed rather than forced into an unsupported combined estimate. Material corporate facts should be cross-checked against issuer filings and exchange documentation before being relied upon.

Questions investors should answer

Before investing, determine the precise legal security held, its quotation and settlement currencies, trading hours, liquidity and bid-ask spread. Confirm any depositary ratio, distribution entitlement, custody costs and conversion charges. Understand how the instrument tracks the underlying issuer and why its return may differ after currency movements. Finally, evaluate the issuer's product portfolio, cash generation, debt obligations, development pipeline and business risks separately from the local trading mechanics.

Frankfurt Stock Exchange and its European role

Frankfurt is an important German and European securities marketplace. Deutsche Börse operates trading venues including Frankfurt Stock Exchange and Xetra, providing access to domestic and international shares alongside funds, bonds and exchange-traded products. A Frankfurt quotation allows investors to access a US issuer through a European market, but it does not turn Pfizer into a German company or change the reporting currency of its consolidated financial statements. The issuer's home market, the trading venue and the quotation currency must be considered separately in financial analysis.

Frankfurt trading hours versus Xetra

Deutsche Börse states that trading at Frankfurt Stock Exchange generally runs from 8 a.m. to 10 p.m. local German time on trading days. Xetra's regular session generally runs from 9 a.m. to 5:30 p.m., with separate extended services subject to their own arrangements. Exchange holidays and special sessions can change these schedules. Frankfurt prices may therefore be observed while the US market is closed or operating under different conditions. A delayed quote should not be described as a real-time executable price.

Trading model, spreads and liquidity

Frankfurt offers specialist-supported trading in parts of its market, while Xetra is associated with electronic order-book trading. Venue structure, market makers, available orders and trading activity influence execution conditions. A globally recognized company does not automatically have deep liquidity on every secondary trading venue. Investors should review the actual trading volume, timestamp, bid-ask spread and order size before drawing conclusions from a last-traded price. Low activity can make the effective transaction cost substantially different from a displayed reference quote.

Currency exposure and comparison with the US listing

This Frankfurt quotation is presented in euros, whereas Pfizer reports consolidated financial results in US dollars. Comparing returns across Frankfurt and New York requires accounting for EUR/USD conversion, trading-session timing, fees, taxes and broker terms. Settlement arrangements should be confirmed with the relevant venue and intermediary rather than assumed to remain fixed. An investor's home-currency return can differ from the local exchange price movement because foreign exchange rates also fluctuate. Apparent cross-market price differences do not guarantee an executable arbitrage opportunity.

Official Frankfurt market information

Deutsche Börse publishes information about its trading calendar, trading hours, available products and execution arrangements. Pfizer's corporate fundamentals should be checked against the issuer's official reports and announcements. The EUR 26.60 quotation discussed here is a delayed reference observation from 27 October 2026, not an automatically refreshed live market feed.

Educational research and dated reference snapshots, not investment advice or live quotes.